Latest News of ZYME
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance |
2 weeks ago
Roche has gained FDA approval for OCREVUS ZUNOVO™, a treatment for multiple sclerosis using Halozyme's ENHANZE® drug delivery technology. The medication is administered as a subcutaneous injection ...
FDA approves Roche's Ocrevus Zunovo with Halozyme Enhanze delivery tech
By Yahoo! Finance |
2 weeks ago
Roche's Ocrevus Zunovo, utilizing Halozyme's Enhanze technology, received FDA approval for subcutaneous injection to treat multiple sclerosis. The new method offers flexibility and efficiency, with co...
Inozyme Pharma, Inc. (INZY) Stock Price, News, Quote & History
By Yahoo! Finance |
1 month ago
Inozyme Pharma specializes in developing treatments for rare diseases affecting vasculature, soft tissue, and skeleton. Their lead product, INZ-701, targets ENPP1 and ABCC6 deficiencies and end-stage ...
-
Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO)
By Yahoo! Finance | 1 month agoMatthew Posard, Director at Halozyme Therapeutics Inc, sold 29,881 shares on August 14, 2024, bringing his total ownership to 69,874 shares. The company focuses on oncology therapies targeting the tum...
-
Zymeworks Inc. (NASDAQ:ZYME) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
By Yahoo! Finance | 2 months agoZymeworks Inc. recently reported disappointing quarterly results, missing revenue predictions. Analysts now expect a significant revenue increase in 2024, but also predict larger losses. Despite this,...
-
Lululemon backs plastic-eating enzyme innovation from Samsara Eco
By Yahoo! Finance | 3 months agoSamsara Eco uses AI to develop plastic-eating enzymes that can break down plastics for infinite recycling. With $65m funding, it plans to build recycling facilities in Southeast Asia with partners lik...
-
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?
By Yahoo! Finance | 3 months agoA list of top biotech penny stocks includes Inozyme Pharma, Inc. (NASDAQ:INZY) showing promise in rare disease therapeutics. Analysts rate it a Strong Buy with potential for significant growth....
-
Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years
By Yahoo! Finance | 3 months agoInvesting in quality companies like Halozyme Therapeutics can lead to significant gains, such as a 193% increase in share price over five years. However, careful analysis of fundamentals is crucial fo...
-
Zymeworks (NASDAQ:ZYME) investors are sitting on a loss of 75% if they invested three years ago
By Yahoo! Finance | 3 months agoZymeworks Inc. (NASDAQ: ZYME) has seen a significant 75% drop in share price over the last three years, with a 16% decrease in the last 90 days....
-
Insider Sale: Director Matthew Posard Sells Shares of Halozyme Therapeutics Inc (HALO)
By Yahoo! Finance | 3 months agoHalozyme Therapeutics Inc is a biopharmaceutical company focusing on oncology therapies targeting the tumor microenvironment. Insider transactions show 17 sells and no buys in the past year. Shares va...
-
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded by Piper Sandler
By Yahoo! Finance | 3 months agoAnalysts on Wall Street lowered ratings for 10 stocks, with Halozyme Therapeutics, Inc. among them. Market movements are cautiously optimistic ahead of crucial US inflation data and the Fed's monetary...